Biophytis SA logo
Biophytis SA BPTS

Annual report 2023
added 12-27-2025

report update icon

Biophytis SA EBITDA 2011-2026 | BPTS

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Biophytis SA

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - -26.8 M -13.9 M -15.7 M -13.9 M -9.7 M -7.77 M -3.12 M -659 K -468 K - -

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
-468 K -26.8 M -10.2 M

References

  1. Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer EBITDA Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
-15.3 M - 5743.5 % $ 69.7 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
-508 M - 2.43 % $ 254 M germanyGermany
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
-6.4 M - 1.35 % $ 17.8 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
-23.9 M - -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
13.8 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
3.11 B - - $ 40.3 B usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
-180 M $ 1.63 - $ 191 M usaUSA
Genfit SA Genfit SA
GNFT
31.8 M - 2.54 % $ 160 B franceFrance
AstraZeneca PLC AstraZeneca PLC
AZN
19.5 B - - $ 96.9 B britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-8.18 M - -1.52 % $ 24.7 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
-73.2 M $ 7.83 - $ 214 M israelIsrael
Athira Pharma Athira Pharma
ATHA
-101 M - - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
-11.9 M - 0.74 % $ 768 M israelIsrael
Galera Therapeutics Galera Therapeutics
GRTX
-2.54 M - -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-8.64 M - -18.52 % $ 27.3 M britainBritain
AbCellera Biologics AbCellera Biologics
ABCL
-199 M $ 4.4 - $ 1.31 B canadaCanada
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
172 M $ 17.3 - $ 809 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-262 M $ 1.59 - $ 423 M britainBritain
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
220 M - - - russiaRussia
BioNTech SE BioNTech SE
BNTX
-1.4 B $ 91.99 - $ 22.2 B germanyGermany
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
-61.4 M - - $ 231 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
-34.6 M $ 3.03 - $ 283 M israelIsrael
Advaxis Advaxis
ADXS
-35.9 M - -9.65 % $ 45.9 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-9.93 M $ 3.49 - $ 5.75 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
-10.7 M - 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-242 M - - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-412 M - - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-16.2 M - - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-55.6 M - 1.93 % $ 17.4 M usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
-18.7 M $ 0.73 - $ 33.4 M israelIsrael
Akero Therapeutics Akero Therapeutics
AKRO
-285 M - - $ 3.67 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
22 K - -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
-62.4 M - -39.0 % $ 4.57 M usaUSA
Akouos Akouos
AKUS
-84.3 M - 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
-123 M - -0.23 % $ 916 M usaUSA
AlloVir AlloVir
ALVR
-46.1 M - 4.14 % $ 49.1 M usaUSA
Allakos Allakos
ALLK
-190 M - - $ 28.6 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
-11.5 M $ 21.57 - $ 2.74 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-47.3 M - 3.16 % $ 1.9 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
-6.28 M $ 9.24 - $ 264 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
60.4 M $ 3.12 - $ 649 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
3.2 M $ 29.96 - $ 806 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
122 K - -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-124 M - - $ 10.1 M usaUSA
Exelixis Exelixis
EXEL
901 M $ 51.1 - $ 13.9 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-57.6 M - - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-50.6 M - 10.36 % $ 9.8 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
-64.5 M - - $ 8.42 M usaUSA
Aravive Aravive
ARAV
-70 M - -13.39 % $ 1.45 M usaUSA